Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) ROE % Adjusted to Book Value : -10.99% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value?

Hemogenyx Pharmaceuticals's ROE % for the quarter that ended in Dec. 2023 was -146.45%. Hemogenyx Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2023 was 13.33. Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -10.99%.

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-42.17

-18.45

-16.82

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial												-12.25	-43.36	-31.48	-5.07	-10.99

Competitive Comparison of Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Calculation

Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-224.16%	/	13.33
	=	-16.82%

Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-146.45%	/	13.33
	=	-10.99%

Hemogenyx Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (Hemogenyx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (OTCPK:HOPHF) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

HEMO:UK 5HU:Germany

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.